Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Ling-Jun Huan"'
Autor:
Onofrio Laselva, Zafar Qureshi, Zhi-Wei Zeng, Evgeniy V. Petrotchenko, Mohabir Ramjeesingh, C. Michael Hamilton, Ling-Jun Huan, Christoph H. Borchers, Régis Pomès, Robert Young, Christine E. Bear
Publikováno v:
iScience, Vol 24, Iss 6, Pp 102542- (2021)
Summary: Ivacaftor (VX-770) was the first cystic fibrosis transmembrane conductance regulator (CFTR) modulatory drug approved for the treatment of patients with cystic fibrosis. Electron cryomicroscopy (cryo-EM) studies of detergent-solubilized CFTR
Externí odkaz:
https://doaj.org/article/8c79a33405ed438787e6e0dfeeeb1030
Autor:
Lei Huang, Wei Qin, Guo-liang Dai, Ming-xing Zhu, Lei-Lei Liu, Ling-Jun Huang, Shan-Pian Yang, Miao-Miao Ge
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-17 (2024)
Abstract Ground settlement prediction for highway subgrades is crucial in related engineering projects. When predicting the ground settlement, sparse sample data are often encountered in practice, which greatly affects the prediction accuracy. Howeve
Externí odkaz:
https://doaj.org/article/2eb45108cae84fcd8773dca98fdea3bf
Autor:
Zhi-Wei Zeng, Zafar Qureshi, Robert N. Young, Christine E. Bear, Evgeniy V. Petrotchenko, Onofrio Laselva, Mohabir Ramjeesingh, Christoph H. Borchers, Ling-Jun Huan, Régis Pomès, C. Michael Hamilton
Publikováno v:
iScience, Vol 24, Iss 6, Pp 102542-(2021)
iScience
iScience
Summary Ivacaftor (VX-770) was the first cystic fibrosis transmembrane conductance regulator (CFTR) modulatory drug approved for the treatment of patients with cystic fibrosis. Electron cryomicroscopy (cryo-EM) studies of detergent-solubilized CFTR i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b2aa429bde997deea7b6708a0a91c64
http://www.sciencedirect.com/science/article/pii/S2589004221005101
http://www.sciencedirect.com/science/article/pii/S2589004221005101
Autor:
Gengming He, Ling Jun Huan, Karen Ho, Leigh Wellhauser, Julie Avolio, Janet Rossant, Sanja Stanojevic, Lianna Kyriakopoulou, Felix Ratjen, Kai Du, Michelle Klingel, Christine E. Bear, Theo J. Moraes, Tanja Gonska, Claire Bartlett, Hong Ouyang, Jia Xin Jiang, Lisa J. Strug, Paul D. W. Eckford, Amy P. Wong, Jacqueline McCormack, Jin Ye Yang, Sergio L. Pereira, Lise Munsie
Publikováno v:
Journal of Cystic Fibrosis. 18:35-43
Background Therapies targeting certain CFTR mutants have been approved, yet variations in clinical response highlight the need for in-vitro and genetic tools that predict patient-specific clinical outcomes. Toward this goal, the CF Canada-Sick Kids P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e878c741dcab4179e1f0c41639a5bbd
https://doi.org/10.1016/j.jcf.2018.03.013
https://doi.org/10.1016/j.jcf.2018.03.013
Autor:
Zeng Zw, Ling Jun Huan, Zafar Qureshi, Régis Pomès, Onofrio Laselva, Evgeniy V. Petrotchenko, Christine E. Bear, Mohabir Ramjeesingh, R. Young, Christoph H. Borchers, M. Hamilton
Publikováno v:
Journal of Cystic Fibrosis. 20:S301
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3e4a4b79736e27ed2f29a73d61bfb59
https://doi.org/10.1016/s1569-1993(21)02057-9
https://doi.org/10.1016/s1569-1993(21)02057-9
Autor:
J.P. Miller, Ling Jun Huan, Saumel Ahmadi, Felix Ratjen, Régis Pomès, Paul D. W. Eckford, Hong Ouyang, Leigh Wellhauser, Christine E. Bear, Adriana Villella, Ellen Li, Theo J. Moraes, Kethika Kulleperuma, Peter N. Ray, Michelle Di Paola, Onofrio Laselva, Steven Molinski, Wan Ip, Po-Shun Lee, Tanja Gonska, Kai Du
Publikováno v:
EMBO Molecular Medicine
The combination therapy of lumacaftor and ivacaftor (Orkambi ® ) is approved for patients bearing the major cystic fibrosis (CF) mutation: ΔF508 . It has been predicted that Orkambi ® could treat patients with rarer mutations of similar “theraty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aaadb2a10accd16a9627ce93c3d4764
http://europepmc.org/articles/PMC5582412
http://europepmc.org/articles/PMC5582412
Autor:
Saumel Ahmadi, Stephanie Chin, Herman Yeger, Kai Du, Mohabir Ramjeesingh, Ling-Jun Huan, Christine E. Bear, Paul Taylor, Stan Pasyk, Michael F. Moran, Steven Molinski
Publikováno v:
PROTEOMICS. 15:447-461
The major cystic fibrosis causing mutation, F508del-CFTR (where CFTR is cystic fibrosis transmembrane conductance regulator), impairs biosynthetic maturation of the CFTR protein, limiting its expression as a phosphorylation-dependent channel on the c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee59295b1785e79aa8adc91d44c1de47
https://doi.org/10.1002/pmic.201400218
https://doi.org/10.1002/pmic.201400218
Autor:
Tadeo Thompson, Janet Rossant, Ling-Jun Huan, Peter Pasceri, Stephanie Chin, Amy P. Wong, Christine E. Bear, James Ellis, Felix Ratjen
Publikováno v:
Nature biotechnology
Cystic fibrosis (CF) is a fatal genetic disease caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene that regulates chloride and water transport across all epithelia and affects multiple organs including the lung
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd786af60cc2bf884e0c33f449936418
https://doi.org/10.1038/nbt.2328
https://doi.org/10.1038/nbt.2328
Autor:
Christine E. Bear, O.C. Snead, Steffany A. L. Bennett, Shawn N. Whitehead, Miguel A. Cortez, S.U. Dhani, Canhui Li, C. D'Antonio, Ling-Jun Huan
Publikováno v:
Neuroscience. 167:154-162
Heterozygous mutations in ClC-2 have been associated in rare cases with increased susceptibility to generalized, idiopathic epilepsy. Initially, it was hypothesized that mutations in ClC-2 may be associated with epilepsy due to a direct role for ClC-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ee012048a53e20e29c3ab7a73a6ad8b
https://doi.org/10.1016/j.neuroscience.2010.01.042
https://doi.org/10.1016/j.neuroscience.2010.01.042
Autor:
Neil B. Sweezey, Patrick Kim Chiaw, Ling-Jun Huan, Diane Ly, Daniela Rotin, Charles M. Deber, Christine E. Bear, Stéphane Gagnon
Publikováno v:
Chemistry & Biology. 16:520-530
SummaryThe cystic fibrosis (CF)-causing mutant, deltaF508-CFTR, is misfolded and fails to traffic out of the endoplasmic reticulum (ER) to the cell surface. Introduction of second site mutations that disrupt a diarginine (RXR)-based ER retention moti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aac6f1e25cab3064bfd29f5354168f8
https://doi.org/10.1016/j.chembiol.2009.04.005
https://doi.org/10.1016/j.chembiol.2009.04.005